Home

Message from our CEO

812x408 Jeffrey Leiden_0.png

Jeffrey Leiden, Chairman, President and CEO

Events & Presentations
1.png
Events and Presentations
3.png
SEC Filings
leadership
Leadership

 

Latest Press Releases

Date Title and Summary
Toggle Summary Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene
- Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - LONDON --(BUSINESS WIRE)--Dec. 10, 2019-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label
General Business
Toggle Summary French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis
LONDON --(BUSINESS WIRE)--Nov. 20, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS ) have approved national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages two and older with
General Business
Toggle Summary CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
-Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with total hemoglobin level of 11.9 g/dL
General Business

Copyright West LLC. Minimum 15 minutes delayed.

IR Contacts

Institutional Analysts and Financial Analysts, please contact:
michael
Michael Partridge
Senior Vice President, Investor Relations
+1(617)-341-6108
eric
Eric Rojas
Senior Director, Investor Relations
+1(617)-961-7205
zach
Zach Barber
Senior Director, Investor Relations
+1(617)-341-6470
leah
Leah Gibson
Associate Director, Investor Relations
+1(617)-961-1507
investor-faq
 
Main Info
Investorinfo@VRTX.com
+1(617)-961-7163

Contacting Vertex's Transfer Agent

Communication regarding transfer requirements, lost certificates and changes of address should be directed to:

Computershare Investor Services

P.O. Box 43023
Providence, RI 02940-3023
Telephone: +1(781)-575-2879
Fax: +1(781)-575-3605